Related Experiment Video
Updated: Mar 28, 2026
11:13
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
2.5K
Combinatorial PX-866 and Raloxifene Decrease Rb Phosphorylation, Cyclin E2 Transcription, and Proliferation of MCF-7
Gregory W Peek1, Trygve O Tollefsbol1,2,3,4,5
1Department of Biology, University of Alabama, Birmingham, Alabama.
Journal of Cellular Biochemistry
|December 15, 2015
Summary
Targeting the TGF-β and PI3K/Akt pathways simultaneously significantly reduces estrogen receptor-positive breast cancer cell proliferation. This dual-pathway approach effectively inhibits cancer cell growth without impacting normal cells.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Understanding complex signaling pathways is crucial for developing targeted breast cancer therapies.
- The human interactome provides a framework for analyzing the composite effects of targeting multiple pathways.
- Characterizing protein-protein interactions is essential for deciphering pathway crosstalk.
Purpose of the Study:
- To investigate the efficacy of a combined therapeutic strategy targeting the TGF-β and PI3K/Akt pathways in breast cancer.
- To evaluate the impact of this dual-pathway inhibition on cell cycle proliferation in estrogen receptor-positive (ER+) breast cancer cells.
- To assess the specificity of the treatment by comparing its effects on cancerous versus non-cancerous breast epithelial cells.
Main Methods:
- MCF-7 (ER+) breast cancer cells and MCF10A (non-cancerous) cells were treated with raloxifene (to upregulate TGF-β) and PX-866 (to down-regulate PI3K/Akt).
- Cell proliferation, phosphorylation status of key proteins (p107, Rb), E2F-1 transcriptional activity, and cyclin expression (including Cyclin E2) were analyzed.
- Statistical significance was determined for all measured outcomes.
Main Results:
- Combined treatment with raloxifene and PX-866 significantly reduced proliferation in MCF-7 cells but not in MCF10A cells.
- A substantial decrease in Rb and p107 phosphorylation was observed, leading to reduced E2F-1 transcriptional activity.
- Decreased expression of E2F-1-regulated Cyclin E2 was noted in response to the combined therapy.
Conclusions:
- Combinational targeting of the TGF-β and PI3K/Akt pathways offers a promising strategy for reducing uncontrolled proliferation of ER+ breast cancer cells.
- The observed effects on cell cycle regulators and gene expression underscore the mechanism of action.
- The specificity of the treatment for cancer cells highlights its potential therapeutic value.
Related Concept Videos
02:34Inhibition of Cdk Activity
6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
02:38Mitogens and the Cell Cycle
8.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K